What is the standard initiating dose of Lantus (insulin glargine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Standard Initiating Dose of Lantus (Insulin Glargine)

For type 2 diabetes patients who are insulin-naive, start Lantus at 0.2 units/kg or up to 10 units once daily, administered at the same time each day. 1

Type 2 Diabetes Starting Dose

The FDA-approved dosing for insulin-naive type 2 diabetes patients is straightforward:

  • Primary recommendation: 0.2 units/kg body weight OR up to 10 units once daily 1
  • The American Diabetes Association guidelines support a starting range of 0.1-0.2 units/kg/day 2, 3, 4
  • For a typical 50 kg patient, this translates to approximately 10 units once daily 4

Lantus should be administered subcutaneously once daily at any time of day, but consistently at the same time every day. 1

Dose Titration Algorithm

After initiation, systematic uptitration is essential to reach glycemic targets:

  • Increase by 2-4 units every 3-4 days until fasting blood glucose reaches target range (80-130 mg/dL) 2, 3, 4
  • More specifically:
    • If fasting glucose ≥180 mg/dL: increase by 4 units every 3 days 4
    • If fasting glucose 140-179 mg/dL: increase by 2 units every 3 days 4
  • Alternative approach: increase by 10-15% of current dose once or twice weekly 4

Type 1 Diabetes Starting Dose

For type 1 diabetes, the approach differs significantly:

  • Start with approximately one-third of total daily insulin requirements as basal insulin 1
  • Total daily insulin requirements typically range from 0.4-1.0 units/kg/day, with 0.5 units/kg/day being typical for metabolically stable patients 3, 4
  • The remaining two-thirds should be provided as short-acting, premeal insulin 1
  • Higher doses (approaching 1.0 units/kg/day) may be required immediately following diabetic ketoacidosis 3

Special Considerations and Common Pitfalls

When to Use Higher Starting Doses

Consider more aggressive initial dosing in type 2 diabetes patients with:

  • HbA1c ≥9% 4
  • Blood glucose levels ≥300-350 mg/dL 4
  • HbA1c 10-12% with symptomatic or catabolic features 4

In these cases, consider starting with 0.3-0.4 units/kg/day or a basal-bolus regimen from the outset 4.

Critical Pitfall: Overbasalization

Be vigilant for overbasalization when basal insulin exceeds 0.5 units/kg/day 2, 4:

  • Clinical signals include:
    • Basal dose >0.5 units/kg/day 2
    • High bedtime-to-morning glucose differential (≥50 mg/dL) 2, 4
    • Hypoglycemia (aware or unaware) 2
    • High glucose variability 2

When basal insulin approaches 0.5-1.0 units/kg/day and A1C remains elevated despite controlled fasting glucose, add prandial insulin rather than continuing to escalate basal insulin 2, 4.

Administration Details

  • Inject subcutaneously into the abdominal area, thigh, or deltoid 1
  • Rotate injection sites within the same region to reduce risk of lipodystrophy 1
  • Never administer intravenously or via insulin pump 1
  • Do not dilute or mix with any other insulin or solution 1

Monitoring Requirements

  • Daily fasting blood glucose monitoring is essential during titration 4
  • Increase frequency of blood glucose monitoring during any insulin regimen changes 1
  • Reassess every 3 days during active titration and every 3-6 months once stable 4

Switching from Other Insulins

When transitioning to Lantus from other basal insulins 1:

  • From once-daily NPH: use the same dose
  • From twice-daily NPH: use 80% of total NPH dose
  • From TOUJEO (U-300 glargine): use 80% of TOUJEO dose

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Insulin Glargine Starting Dose Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Initial Dosing for Lantus (Insulin Glargine) in Patients Requiring Insulin Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.